Recent advances in JAK inhibitors for the treatment of metabolic syndrome
Frontiers in Pharmacology · 24.08.2023 · 14
DOI: 10.3389/fphar.2023.1245535 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 24.08.2023. Verfasst von Debora Collotta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience "Rita Levi-Montalcini", University of Turin, Turin, Italy. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
With an epidemic spread, metabolic syndrome represents an increasingly emerging risk for the population globally, and is currently recognized as a pathological entity. It is represented by a cluster of different conditions including increased blood pressure, high blood sugar, excess body fat around the waist and abnormal cholesterol or triglyceride levels. These conditions lead directly to several disorders, including obesity, dyslipidemia, hyperglycaemia, insulin resistance, impaired glucose tolerance and hypertension causing an increase in cardiovascular risk and in particular atherosclerotic disease. Despite efforts to promote healthier lifestyles through exercise, reduced caloric intake, and improved dietary choices, the incidence and prevalence of metabolic syndrome continue to rise worldwide. Recent research has highlighted the involvement of signaling pathways in chronic inflammatory conditions like obesity and type 2 diabetes mellitus, revealing the significance of the JAK/STAT pathway in atherosclerotic events. This pathway serves as a rapid membrane-to-nucleus signaling module that regulates the expression of critical mediators. Consequently, JAK inhibitors (JAKi) have emerged as potential therapeutic options for metabolic diseases, offering a promising avenue for intervention. The aim of this review is to shed light on the emerging indications of JAK inhibitors in metabolic syndrome, emphasizing their potential role in attenuating associated inflammatory processes, improving insulin sensitivity, and addressing cross-talk with the insulin pathway, with the intention of contributing to efforts in the field of inflammation pharmacology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroscience "Rita Levi-Montalcini", University of Turin, Turin, Italy.
- Chemsafe S.r.l., Turin, Italy.
Zitieren
APA
Collotta, D., Franchina, M. P., Carlucci, V., & Collino, M. (2023). Recent advances in JAK inhibitors for the treatment of metabolic syndrome. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1245535
Vancouver
Collotta D, Franchina MP, Carlucci V, Collino M. Recent advances in JAK inhibitors for the treatment of metabolic syndrome. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1245535
BibTeX
@article{Collotta2023,
author = {Collotta, Debora and Franchina, Maria Paola and Carlucci, Virginia and Collino, Massimo},
title = {Recent advances in JAK inhibitors for the treatment of metabolic syndrome},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1245535}
}
EUVIMED